CO-SPATIAL-CORP
30.4.2024 09:01:33 CEST | Business Wire | Press release
Spatial Corp, the leading software development toolkit provider for design, manufacturing, and engineering solutions and Dassault Systèmes subsidiary, announces the production release of 2024 1.0.1.
Data Prep Is Officially Released
Open New Horizons in Data Import
After launching the alpha version, Data Prep, Spatial’s newest add-on product for 3D InterOp, is officially released to all customers. Supported strategies include filtering small bodies from a model, removing small holes and fillets, and generating an assembly structure from a part with duplicate bodies.
Over the past three months, customer interest confirms the market need for tools to simplify and optimize data during import. Spatial plans to invest further in Data Prep strategies. Functionality releasing soon includes:
- Capabilities to reduce data to manage while preserving relevant features - to shorten model preparation times for multi-physics and process simulation workflows.
- Ability to convert polyline data to continuous curves during file restore - to decrease memory consumption and allow for successful import.
- Option to avoid model shrinkage due to Data Prep strategies like feature removal - to ensure accuracy of collision detection analyses.
Users interested in defining future strategies for Data Prep should contact their account manager.
3D InterOp Extends Support for BIM and Manufacturing
New Support for Navisworks and Writing DXF/DWG Drawing Sheets
The latest release allows BIM customers to read Navisworks files and write drawing sheets in a DXF/DWG format. Additionally, 3D InterOp offers expanded support for the Linux platform in Parasolid-based 3D InterOp.
Point and Table Patterns from Creo Files
Manufacturing relies on hole pattern metadata for automated machining processes such as drilling, milling, cutting, or punching. The latest release of 3D InterOp supports Point and Table type hole patterns in Creo Reader.
Enabling Support of More Formats through External Partners
Extensible 3D InterOp enables partners to create readers and writers for unsupported file formats. These external implementations integrate with existing formats to seamlessly exchange BREP and Visualization data. Customers wishing to develop custom readers and writers can reach out to their account manager for assistance.
Package Size Optimization
For customers not needing support for all bundled formats, ACIS-based 3D InterOp offers guidance on configuring a minimal library set for popular CAD and exchange formats. This minimizes the libraries shipped with their application, saving end-user disk space. For example, supporting only IGES + STEP formats reduces installed library size by 70%.
3D ACIS Modeler Improves Polyhedral Modeling
Polyhedral Sheet Thickening
Additive manufacturing or EDA workflows often start with input that is a 2D representation of a thin part to be processed. When printing or simulating the part, generating a realistic 3D model representing the object with its actual thickness is helpful. This release delivers an API to generate a thickened body from polyhedral sheets.
New Polyhedral Boolean Operations
ACIS now provides functionality to compute the intersection graph between two polyhedral bodies. It also allows combining disjointed polyhedral bodies into a single body, increasing the efficiency of downstream operations.
CGM Provides More Manufacturing Automation and Simulation Tools
Enhancements to Feature Recognition and Removal
Users can now specify an industry context to customize the behavior of feature recognition. Setting the industry context tailors feature recognition to provide intuitive results for applications as diverse as Body-in-White, Micro-Mechanics, and Civil Engineering. This release also offers functionality to remove chamfers.
Improved Polyhedral Modeling for Additive Manufacturing
This release provides various robustness and performance enhancements targeting polyhedral healing and offset. For both types of operations, options are now available to tune the performance for specific configurations.
New Medial Axis Extraction Operator
Simulation engineers need tools to simplify the geometry of parts to reduce analysis computation time. This release features the beta version of the Neutral Fiber Operator, which reduces radially symmetric 3D bodies to a one-dimensional line.
CSM/CVM: Improvements to Cartesian Core Workflows
CVM generates Cartesian elements for interior meshing, resulting in accurate triangular surface meshes and predominantly hexahedral volume meshes. Users can now control the size of these elements, which were previously determined automatically based on surface mesh element size.
About Spatial Corp.
Spatial Corp, a Dassault Systèmes subsidiary, is the leading provider of 3D software development toolkits for technical applications across a broad range of industries. Spatial 3D modeling, 3D visualization, and CAD translation software development toolkits help application developers deliver market-leading products, maintain focus on core competencies, and reduce time-to-market. For over 35 years, Spatial’s 3D software development toolkits have been adopted by many of the world’s most recognized software developers, manufacturers, research institutes, and universities. Headquartered in Broomfield, Colorado, Spatial has offices in the USA, Germany, Japan, China, and the United Kingdom. For more information, visit www.spatial.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430297301/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
